Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00175955
Status:
COMPLETED
Last Update Posted:
2013-12-06
First Post:
2005-09-09
Brief Title:
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
An 8-week Exploratory Double-blind Placebo Controlled Randomized Trial Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mgDay 250-500 mg Oral Tablets in bid Administration on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder Aged From at Least 18 Years to 80 Years
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT Number 2004-001302-27 | None | None | None |